The Journal of allergy and clinical immunology
-
J. Allergy Clin. Immunol. · Jan 2020
Retraction Of PublicationTEMPORARY REMOVAL: Update on the NAEPP asthma guidelines: The wait is over, or is it?
The publisher regrets that this article has been temporarily removed. A replacement will appear as soon as possible in which the reason for the removal of the article will be specified, or the article will be reinstated. The full Elsevier Policy on Article Withdrawal can be found at https://www.elsevier.com/about/our-business/policies/article-withdrawal.
-
J. Allergy Clin. Immunol. · Jan 2020
Randomized Controlled Trial Multicenter StudyPhase 2B randomized study of nemolizumab in adults with moderate-to-severe atopic dermatitis and severe pruritus.
Nemolizumab targets the IL-31 receptor α subunit involved in atopic dermatitis (AD) pathogenesis. ⋯ Nemolizumab resulted in rapid and sustained improvements in cutaneous signs of inflammation and pruritus in patients with AD, with maximal efficacy observed at 30 mg. Nemolizumab had an acceptable safety profile.